NCT03872661 2024-12-06
NIBCUN
Sun Yat-sen University
Phase 2 Recruiting
Clinical Trials
10 trialsNCT04973293 2024-11-19
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Ruijin Hospital
Phase NA Recruiting
NCT06688656 2024-11-14
Peri-E
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT05400070 2024-10-18
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Tang-Du Hospital
Phase 2 Active not recruiting
NCT04790409 2023-09-14
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Phase 2 Completed
NCT03607539 2023-02-27
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04513301 2020-08-14
Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study
Shanghai Cancer Hospital, China
Phase 2 Unknown
NCT04486287 2020-07-24
Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04189094 2019-12-06
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT03765775 2018-12-06
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
First Hospital of Shijiazhuang City
Phase 2 Unknown